Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical stage bio-pharmaceutical company. The Company is engaged in the developments drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, and various types of cancer.
IPO Date: October 7, 2015
Sector: Healthcare
Industry: Biotech
Market Cap: $948.98M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.24 | 3.45%
Avg Daily Range (30 D): $0.28 | 2.98%
Avg Daily Range (90 D): $0.26 | 2.93%
Institutional Daily Volume
Avg Daily Volume: .98M
Avg Daily Volume (30 D): .73M
Avg Daily Volume (90 D): .81M
Trade Size
Avg Trade Size (Sh.): 154
Avg Trade Size (Sh.) (30 D): 86
Avg Trade Size (Sh.) (90 D): 90
Institutional Trades
Total Inst.Trades: 1,279
Avg Inst. Trade: $1.5M
Avg Inst. Trade (30 D): $1.53M
Avg Inst. Trade (90 D): $1.32M
Avg Inst. Trade Volume: .15M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.59M
Avg Closing Trade (30 D): $1.47M
Avg Closing Trade (90 D): $1.29M
Avg Closing Volume: 168.49K
   
News
Jun 16, 2025 @ 10:38 PM
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announce...
Source: N/A
Apr 5, 2025 @ 3:30 PM
Anavex Life Sciences Announces Positive up to 4-Ye...
Source: N/A
Dec 27, 2024 @ 3:08 PM
Anavex Life Sciences: Short-Squeeze Target Gains T...
Source: Thomas Hughes
Dec 23, 2024 @ 11:26 AM
US Stocks To Open Higher As Wall Street Expects 'S...
Source: Rishabh Mishra
Nov 8, 2024 @ 11:28 PM
Friday's Top 5 Trending Stocks: What's The Scoop O...
Source: Erica Kollmann
Financials
  TTM Q2 2025 Q1 2025
Basic EPS $-.55 $-.13 $-.14
Diluted EPS $-.55 $-.13 $-.14
Revenue $ 6.16M $ 1.21M $ 1.39M
Gross Profit $ $ $
Net Income / Loss $ -47.14M $ -11.2M $ -12.11M
Operating Income / Loss $ -55.17M $ -12.51M $ -13.59M
Cost of Revenue $ $ $
Net Cash Flow $ M $ M $ M
PE Ratio    
Splits
Oct 07, 2015:   1:4
Jun 12, 2006:   6:1